Cellectar Biosciences shares surge 14.89% premarket after securing key patents for iopofosine I 131 ahead of EMA filing.
ByAinvest
Tuesday, Feb 17, 2026 8:20 am ET1min read
CLRB--
Cellectar Biosciences (NASDAQ: CLRB) surged 14.89% in premarket trading following the announcement of expanded global intellectual property (IP) protection for its cancer-targeting drug candidates. The company secured new patents across Europe, Asia-Pacific, the Middle East, and the Americas, covering iopofosine I 131 (a radiotherapeutic for Waldenström macroglobulinemia) and CLR-125 (an Auger-emitting radiopharmaceutical for triple-negative breast cancer). These patents strengthen IP coverage ahead of a planned 3Q26 conditional marketing authorization filing with the European Medicines Agency (EMA) for iopofosine I 131. The CEO emphasized the strategic importance of these patents in fortifying the company’s portfolio and supporting long-term commercial goals. The news reinforced investor confidence in Cellectar’s pipeline advancements and regulatory progress, directly aligning with the stock’s premarket gains.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet